<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34303">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660034</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317/BGB-290_Study_001</org_study_id>
    <nct_id>NCT02660034</nct_id>
  </id_info>
  <brief_title>The Safety, Pharmacokinetics and Antitumor Activity of the BGB-A317 in Combination With the BGB-290 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myriad Genetic Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiGene</source>
  <brief_summary>
    <textblock>
      The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody
      BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid
      Tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1A: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>from signing the informed consent form (ICF) and throughout the study (2 years of active therapy)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1B: Objective Response Rate (ORR) as evaluated by the investigators separately for each arm</measure>
    <time_frame>Every 9 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1A and 1B: Serum concentrations of BGB-A317</measure>
    <time_frame>pre-dose and at 4 hours in Cycles 2 (each cycle is 21 days), 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1A and 1B: Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast) at steady state for BGB-290</measure>
    <time_frame>Part A and B: day 1 in Cycle 2 (each cycle is 21 days), and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1A and 1B: Maximum plasma concentration (Cmax) at steady state for BGB-290</measure>
    <time_frame>Part A and B: day 1 in Cycle 2 (each cycle is 21 days), and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1A and 1B: Time to reach maximum plasma concentration (tmax) at steady state for BGB-290</measure>
    <time_frame>Part A and B: day 1 in Cycle 2 (each cycle is 21 days), and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1A and 1B: disease control rate (DCR)</measure>
    <time_frame>Every 9 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1A and 1B: Clinical benefit rate (CBR)</measure>
    <time_frame>Every 9 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 24 subjects for the dose escalation until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 100 subjects for expansion in four selected cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BGB-A317</intervention_name>
    <arm_group_label>Phase 1A</arm_group_label>
    <arm_group_label>Phase 1B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-290</intervention_name>
    <arm_group_label>Phase 1A</arm_group_label>
    <arm_group_label>Phase 1B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects have voluntarily agreed to participate by giving written informed consent.

          2. Subjects have advanced tumor who failed at least 1 prior chemotherapy.

          3. In Part A, the subjects must have a histologically or cytologically confirmed
             advanced tumor.

          4. In Part B, the subjects recruited to one of the four expansion arms must have
             histologically or cytologically confirmed advanced solid tumor with BRCA1/2 mutation
             or with documented HR or MMR deficiency.

          5. Subjects must have measurable disease as defined per the RECIST version 1.1.

          6. Male or female ≥ 18 years of age on the day of signing informed consent.

          7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1.

          8. Life expectancy ≥ 12 weeks.

          9. Subject must have adequate organ function as indicated by the following laboratory
             values.

               1. Absolute neutrophil count (ANC) ≥ 1,500/mL

               2. Platelets ≥ 100,000/mL

               3. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L

               4. Serum creatinine ≤ 1.5 × upper limit of normal (ULN)

               5. Serum total bilirubin ≤ 1.5 × ULN (On fractionation ≤ 90% of total bilirubin
                  should be unconjugated).

               6. Aspartate aminotransferase (serum glutamic oxaloacetic transaminase [SGOT]) and
                  alanine aminotransferase (serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 ×
                  ULN or ≤ 5 × ULN for subjects with liver metastases

               7. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN

               8. Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN

         10. Female subjects are eligible to enter and participate in the study if they are of:

               1. Non-childbearing potential (i.e., physiologically incapable of becoming
                  pregnant)

               2. Childbearing potential, has a negative serum pregnancy test at screening (within
                  7 days of the first investigational product administration), is not breast
                  feeding, and uses adequate contraception before study entry and throughout the
                  study until 90 days after the last investigational product administration.

         11. Male subjects are eligible to enter and participate in the study if they are
             vasectomized or agree to use of contraception during the study treatment period and
             for at least 180 days after the last dose of the study drug.

        Exclusion Criteria:

          1. History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)

          2. Prior malignancy within the previous 2 years except for locally curable cancers that
             have been apparently cured, such as basal or squamous cell skin cancer, superficial
             bladder cancer or carcinoma in situ of the cervix or breast

          3. Prior therapies targeting PD-1, programmed death-ligand 1 (PD-L1), or PARP

          4. Subjects with active autoimmune diseases or history of autoimmune diseases should be
             excluded;

          5. Subjects should be excluded if they have a condition requiring systemic treatment
             with either corticosteroids (&gt; 10 mg daily prednisone equivalents) or other
             immunosuppressive medications within 14 days of the study drug administration.

          6. Has history of interstitial lung disease or non-infectious pneumonitis except for
             those induced by radiation therapies.

          7. Known history of human immunodeficiency virus (HIV);

          8. Active infection requiring therapy, positive tests for hepatitis B surface antigen
             (HBsAg) or hepatitis C ribonucleic acid (RNA);

          9. Underlying medical conditions that, in the investigator's opinion, will make the
             administration of study drug hazardous or obscure the interpretation of toxicity
             determination or adverse events (AEs);

         10. Inability to swallow oral medications (capsules and tablets) without chewing,
             breaking, crushing, opening or otherwise altering the product formulation.

         11. Prior chemotherapy, radiotherapy, immunotherapy or any investigational therapies used
             to control cancer must have been completed at least 4 weeks or at least 5 half-lives
             (whichever is shorter) before the study drug administration, and all AEs have either
             returned to baseline or stabilized.

         12. Use of any vaccines (e.g., against infectious diseases such as influenza and
             varicella) within 4 weeks (28 days) of initiation of study therapy and 60 days after
             the last administration of the study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Du, MD.</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sean Du, MD.</last_name>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 27, 2016</lastchanged_date>
  <firstreceived_date>January 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose Escalation</keyword>
  <keyword>Dose Expansion</keyword>
  <keyword>BGB-A317</keyword>
  <keyword>BGB-290</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
